Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases

  1. Yanxia Bi
  2. Jian Su
  3. Shengru Zhou
  4. Yingjie Zhao
  5. Yan Zhang
  6. Huihui Zhang
  7. Mingdong Liu
  8. Aiwu Zhou
  9. Jianrong Xu
  10. Meng Pan  Is a corresponding author
  11. Yiming Zhao  Is a corresponding author
  12. Fubin Li  Is a corresponding author
  1. Shanghai Jiao Tong University, China
  2. First Affiliated Hospital of Soochow University, China

Abstract

IgG4 is the least potent human IgG subclass for the FcγR-mediated antibody effector function. Paradoxically, IgG4 is also the dominant IgG subclass of pathogenic autoantibodies in IgG4-mediated diseases. Here we show that the IgG subclass and Fc-FcγR interaction have a distinct impact on the pathogenic function of autoantibodies in different IgG4-mediated diseases in mouse models. While IgG4 and its weak Fc-FcγR interaction have an ameliorative role in the pathogenicity of anti-ADAMTS13 autoantibodies isolated from thrombotic thrombocytopenic purpura (TTP) patients, they have an unexpected exacerbating effect on anti-Dsg1 autoantibody pathogenicity in pemphigus foliaceus (PF) models. Strikingly, a non-pathogenic anti-Dsg1 antibody variant optimized for FcγR-mediated effector function can attenuate the skin lesions induced by pathogenic anti-Dsg1 antibodies by promoting the clearance of dead keratinocytes. These studies suggest that IgG effector function contributes to the clearance of autoantibody-Ag complexes, which is harmful in TTP, but beneficial in PF and may provide new therapeutic opportunity.

Data availability

All data and materials generated or analyzed during this study are either included in this manuscript (Figures and supplementary information) or available upon reasonable request.

Article and author information

Author details

  1. Yanxia Bi

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    Yanxia Bi, A patent application based on the study has been submitted (Chinese patent application number: 202011408005.X), and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors..
  2. Jian Su

    Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
    Competing interests
    No competing interests declared.
  3. Shengru Zhou

    Department of Dermatology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    No competing interests declared.
  4. Yingjie Zhao

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    No competing interests declared.
  5. Yan Zhang

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    Yan Zhang, A patent application based on the study has been submitted (Chinese patent application number: 202011408005.X), and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors..
  6. Huihui Zhang

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    Huihui Zhang, A patent application based on the study has been submitted (Chinese patent application number: 202011408005.X), and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors..
  7. Mingdong Liu

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    No competing interests declared.
  8. Aiwu Zhou

    Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    No competing interests declared.
  9. Jianrong Xu

    Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    Competing interests
    No competing interests declared.
  10. Meng Pan

    Department of Dermatology, Shanghai Jiao Tong University, Shanghai, China
    For correspondence
    pm10633@rjh.com.cn
    Competing interests
    No competing interests declared.
  11. Yiming Zhao

    Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China
    For correspondence
    zhaoyimingbox@163.com
    Competing interests
    No competing interests declared.
  12. Fubin Li

    Shanghai Institute of Immunology, Shanghai Jiao Tong University, Shanghai, China
    For correspondence
    fubin.li@sjtu.edu.cn
    Competing interests
    Fubin Li, A patent application based on the study has been submitted (Chinese patent application number: 202011408005.X), and Fubin Li, Yanxia Bi, Yan Zhang, and Huihui Zhang are listed as inventors..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6268-3378

Funding

National Natural Science Foundation of China (31422020)

  • Fubin Li

National Natural Science Foundation of China (31870924)

  • Fubin Li

National Natural Science Foundation of China (81873431)

  • Yiming Zhao

Jiangsu Provincial Natural Science Foundation (BK20181164.)

  • Yiming Zhao

Shanghai Sailing Program (16YF1409700)

  • Yan Zhang

Shanghai Municipal Natural Science Foundation project (15ZR1436400)

  • Huihui Zhang

Shanghai Young Oriental scholar program 2015

  • Huihui Zhang

Innovative research team of high-level local universities in Shanghai (SSMU-2DCX20180100)

  • Yan Zhang
  • Huihui Zhang
  • Fubin Li

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mice were bred and maintained under specific pathogen-free (SPF) conditions, and all animal experiments were performed under the institutional guidelines of the Shanghai Jiao Tong University School of Medicine Institutional Animal Care and Use Committee (Protocol Registry Number: A-2015-014).

Human subjects: Ethical approval was obtained from the Ethics Committees in The Rui Jin Hospital of Shanghai Jiao Tong University School of Medicine and The First Affiliated Hospital of Soochow University, respectively. All PF and TTP patients and healthy volunteers signed informed consent.

Copyright

© 2022, Bi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,411
    views
  • 296
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yanxia Bi
  2. Jian Su
  3. Shengru Zhou
  4. Yingjie Zhao
  5. Yan Zhang
  6. Huihui Zhang
  7. Mingdong Liu
  8. Aiwu Zhou
  9. Jianrong Xu
  10. Meng Pan
  11. Yiming Zhao
  12. Fubin Li
(2022)
Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases
eLife 11:e76223.
https://doi.org/10.7554/eLife.76223

Share this article

https://doi.org/10.7554/eLife.76223

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.